CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 600 target
Drug / intervention
Atorvastatin 40mg +1 moredrug
Likely dose
Atorvastatin 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06358313
NCT06358313Phase 3RecruitingMonitorUpdated 2mo ago · Completion was 1mo ago
Slow Enrollment
Monitor

Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke, a Randomized Controlled Single-blinded Trial

Kafrelsheikh University·interventional·Posted Apr 10, 2024·Updated Apr 23, 2026

In Brief

A Phase 3 clinical trial evaluating Atorvastatin 40mg and Rosuvastatin 20mg for Ischemic Stroke. Currently recruiting, targeting 600 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever small vessel stroke patients treated with clopidogrel and aspirin assessed through NIHSS, mRS, and possible adverse effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesEgypt
Collaborators--

Timeline

Phase 3RecruitingOverdue
20252026
First PostedApr 10, 2024
Enrollment StartApr 10, 2024
Primary CompletionMay 10, 2026
Study CompletionMay 30, 2026
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 2.2 years ago

Interventions

Atorvastatin 40mgdrug

The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.

Rosuvastatin 20mgdrug

The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.